Larvol Delta - Viracta-announces-positive-phase-1b2-data-presented-at-oral-presentation-on-lead-program-for-EpsteinBarr-Virus-EBVassociated-relapsedrefractory-lymphomas-at-the-2019-American-Society-of-Hematology-ASH-Annual-Meeting

tractinostat (VRx-3996) - Viracta Therapeutics

https://www.prnewswire.com/news-releases/viracta-announces-positive-phase-1b2-data-presented-at-oral-presentation-on-lead-program-for-epstein-barr-virus-ebv-associated-relapsedrefractory-lymphomas-at-the-2019-american-society-of-hematology-ash-annual-meeting-300971007.html

Dec 8, 2019

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next